Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19110605 | 0.88 | LMNA (0.45) | HTR7HTR1AHTR2A | |
| SCHEMBL17317909 | 0.84 | NR1H2 (0.44) | HTR7NR1H2NR1H3RIPK3MCHR1 | |
| Hydrochloric Acid SCHEMBL17317524 | 0.84 | NR1H2 (0.44) | HTR7NR1H2NR1H3RIPK3GRM2 | |
| SCHEMBL19110602 | 0.83 | CYP1A2 (0.40) | HTR7PDE5AHTR1AHTR2A | |
| SCHEMBL19110587 | 0.82 | HTR7 (0.53) | HTR7HTR1AHTR2A | |
| SCHEMBL19110655 | 0.79 | HTR7 (0.43) | HTR7HTR1AHTR2A | |
| SCHEMBL19110586 | 0.78 | SLC2A1 (0.48) | HTR7 | |
| SCHEMBL17317631 | 0.77 | PNMT (0.40) | HTR7NR1H2NR1H3RIPK3GRM2 | |
| Hydrochloric Acid SCHEMBL17317645 | 0.76 | PNMT (0.40) | HTR7NR1H2NR1H3RIPK3MCHR1 | |
| SCHEMBL19110591 | 0.75 | HTR7 (0.54) | HTR7HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | HTR7 755/4885PDE5A 411/4885NR1H2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.